PMID- 31881222
OWN - NLM
STAT- MEDLINE
DCOM- 20200128
LR  - 20200128
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Linking)
VI  - 242
DP  - 2020 Feb 1
TI  - Cord blood stem cell derived CD16(+) NK cells eradicated acute lymphoblastic 
      leukemia cells using with anti-CD47 antibody.
PG  - 117223
LID - S0024-3205(19)31151-8 [pii]
LID - 10.1016/j.lfs.2019.117223 [doi]
AB  - Acute lymphoblastic leukemia (ALL) is an aggressive cancer in children and adults 
      which possess higher CD47 expression than normal cells. ALL chemotherapy has a 
      lot of side effects and in most cases is ineffective. However arrival of Natural 
      killer (NK) cell immunotherapy raised hopes for successful treatment of cancers, 
      tailoring NK cells to meet clinical requirements is still under investigation. Of 
      note, CD16(+) (FCgammaIIIa) NK cells eliminate tumor cells with antibody dependent 
      cell cytotoxicity (ADCC) mechanism. Therefore, we evaluated ADCC effect of cord 
      blood stem cell derived CD16(+) NK cells with using anti CD47 blocking antibody. 
      CD16(+) NK cells generated efficiently from CD34 positive cord blood cells in 
      vitro using IL-2, IL-15 and IL-21 cytokines, although it was not dose dependent. 
      CD16(+) cells derived from CD34(+) cells in day 14 of culture efficiently 
      increased apoptosis in ALL cells, produced INFgamma and increased CD107-a expression 
      when used anti CD47 antibody (increased around 30-40%). Interestingly, CD16(+) NK 
      cell cytotoxicity slightly increased in combination with macrophages against ALL 
      cells (around 10%). Taken together, our findings induced this hope that cord 
      blood stem cell derived CD16(+) NK cells exploit antitumor immune response in 
      cancer therapy with using anti-CD47 antibody.
CI  - Copyright (c) 2019 Elsevier Inc. All rights reserved.
FAU - Valipour, Behnaz
AU  - Valipour B
AD  - Stem Cell Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran; 
      Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; 
      Department of Anatomical Sciences, Faculty of Medicine, Tabriz University of 
      Medical Sciences, Tabriz, Iran.
FAU - Abedelahi, Ali
AU  - Abedelahi A
AD  - Department of Anatomical Sciences, Faculty of Medicine, Tabriz University of 
      Medical Sciences, Tabriz, Iran.
FAU - Naderali, Elahe
AU  - Naderali E
AD  - Stem Cell Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Velaei, Kobra
AU  - Velaei K
AD  - Department of Anatomical Sciences, Faculty of Medicine, Tabriz University of 
      Medical Sciences, Tabriz, Iran.
FAU - Movassaghpour, Aliakbar
AU  - Movassaghpour A
AD  - Hematology and Oncology Research Center, Tabriz University of Medical Sciences, 
      Tabriz, Iran.
FAU - Talebi, Mehdi
AU  - Talebi M
AD  - Hematology and Oncology Research Center, Tabriz University of Medical Sciences, 
      Tabriz, Iran.
FAU - Montazersaheb, Soheila
AU  - Montazersaheb S
AD  - Molecular Medicine Research Center, Tabriz University of Medical Sciences, 
      Tabriz, Iran.
FAU - Karimipour, Mohammad
AU  - Karimipour M
AD  - Department of Anatomical Sciences, Faculty of Medicine, Tabriz University of 
      Medical Sciences, Tabriz, Iran.
FAU - Darabi, Masoud
AU  - Darabi M
AD  - Biochemistry Department, Faculty of Medicine, Tabriz University of Medical 
      Sciences.
FAU - Chavoshi, Hadi
AU  - Chavoshi H
AD  - Hematology and Oncology Research Center, Tabriz University of Medical Sciences, 
      Tabriz, Iran.
FAU - Nozad Charoudeh, Hojjatollah
AU  - Nozad Charoudeh H
AD  - Stem Cell Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran. 
      Electronic address: nozadh@tbzmed.ac.ir.
LA  - eng
PT  - Journal Article
DEP - 20191224
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (CD47 Antigen)
RN  - 0 (Receptors, IgG)
SB  - IM
MH  - Antibodies, Anti-Idiotypic/immunology/*therapeutic use
MH  - Blotting, Western
MH  - CD47 Antigen/*immunology
MH  - Cell Line, Tumor
MH  - *Cord Blood Stem Cell Transplantation
MH  - Flow Cytometry
MH  - Humans
MH  - Immunotherapy/methods
MH  - Killer Cells, Natural/*immunology
MH  - Microscopy, Fluorescence
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*immunology/therapy
MH  - Receptors, IgG/*immunology
OTO - NOTNLM
OT  - ADCC
OT  - Acute lymphoblastic leukemia
OT  - CD16 receptor
OT  - CD47
OT  - Macrophages
OT  - Natural killer cells
EDAT- 2019/12/28 06:00
MHDA- 2020/01/29 06:00
CRDT- 2019/12/28 06:00
PHST- 2019/10/30 00:00 [received]
PHST- 2019/12/18 00:00 [revised]
PHST- 2019/12/22 00:00 [accepted]
PHST- 2019/12/28 06:00 [pubmed]
PHST- 2020/01/29 06:00 [medline]
PHST- 2019/12/28 06:00 [entrez]
AID - S0024-3205(19)31151-8 [pii]
AID - 10.1016/j.lfs.2019.117223 [doi]
PST - ppublish
SO  - Life Sci. 2020 Feb 1;242:117223. doi: 10.1016/j.lfs.2019.117223. Epub 2019 Dec 
      24.